Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Madurella mycetomatis is highly susceptible to ravuconazole.

Ahmed SA, Kloezen W, Duncanson F, Zijlstra EE, de Hoog GS, Fahal AH, van de Sande WW.

PLoS Negl Trop Dis. 2014 Jun 19;8(6):e2942. doi: 10.1371/journal.pntd.0002942. eCollection 2014 Jun.

2.

In vitro antifungal activity of isavuconazole against Madurella mycetomatis.

Kloezen W, Meis JF, Curfs-Breuker I, Fahal AH, van de Sande WW.

Antimicrob Agents Chemother. 2012 Nov;56(11):6054-6. doi: 10.1128/AAC.01170-12. Epub 2012 Sep 10.

3.

In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine.

van Belkum A, Fahal AH, van de Sande WW.

Antimicrob Agents Chemother. 2011 Apr;55(4):1771-3. doi: 10.1128/AAC.01045-10. Epub 2011 Jan 24.

4.

Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole.

van de Sande WW, de Kat J, Coppens J, Ahmed AO, Fahal A, Verbrugh H, van Belkum A.

Microbes Infect. 2007 Jul;9(9):1114-23. Epub 2007 May 18.

PMID:
17644456
5.

Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents.

van de Sande WW, Fahal AH, Bakker-Woudenberg IA, van Belkum A.

Antimicrob Agents Chemother. 2010 Jun;54(6):2738-40. doi: 10.1128/AAC.01546-09. Epub 2010 Mar 29.

7.

In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans.

Yamazumi T, Pfaller MA, Messer SA, Houston A, Hollis RJ, Jones RN.

Antimicrob Agents Chemother. 2000 Oct;44(10):2883-6.

10.
11.

In vitro susceptibility of Madurella mycetomatis, prime agent of Madura foot, to tea tree oil and artemisinin.

van de Sande WW, Fahal AH, Riley TV, Verbrugh H, van Belkum A.

J Antimicrob Chemother. 2007 Mar;59(3):553-5.

PMID:
17324961
12.

In vitro interaction of currently used azoles with terbinafine against Madurella mycetomatis.

Ahmed SA, Kloezen W, Fahal AH, de Hoog GS, van de Sande WW.

Antimicrob Agents Chemother. 2015 Feb;59(2):1373-4. doi: 10.1128/AAC.04487-14. Epub 2014 Dec 8. No abstract available.

15.

In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates.

Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Garcia-Effron G, Rodriguez-Tudela JL.

Antimicrob Agents Chemother. 2004 Aug;48(8):3107-11.

16.

New species of Madurella, causative agents of black-grain mycetoma.

de Hoog GS, van Diepeningen AD, Mahgoub el-S, van de Sande WW.

J Clin Microbiol. 2012 Mar;50(3):988-94. doi: 10.1128/JCM.05477-11. Epub 2012 Jan 11.

17.

The in vitro antifungal activity of sudanese medicinal plants against Madurella mycetomatis, the eumycetoma major causative agent.

Elfadil H, Fahal A, Kloezen W, Ahmed EM, van de Sande W.

PLoS Negl Trop Dis. 2015 Mar 13;9(3):e0003488. doi: 10.1371/journal.pntd.0003488. eCollection 2015 Mar.

18.

Antimycotic susceptibility testing of agents of black grain eumycetoma.

Venugopal PV, Venugopal TV, Ramakrishna ES, Ilavarasi S.

J Med Vet Mycol. 1993;31(2):161-4.

PMID:
8389847
19.

In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates.

Minassian B, Huczko E, Washo T, Bonner D, Fung-Tomc J.

Clin Microbiol Infect. 2003 Dec;9(12):1250-2. No abstract available.

20.

Supplemental Content

Support Center